The Bethesda Declaration, a new RSV antibody for kids, amylin’s promising weight loss results, and more were industry’s need-to-know stories this week.
After tragedy struck during a 1960s clinical trial, development of a vaccine for RSV ground to a halt. But as new RSV vaccine candidates enter late-stage clinical trials, a safe and effective vaccine is finally in sight.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?